F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma

Successful treatment of nonsmall cell lung carcinoma (NSCLC) with radical radiotherapy (RT) requires accurate delineation of tumor extent. Conventional computed tomography–based noninvasive staging often estimates intrathoracic thoracic tumor extent incorrectly and fails to detect distant metastasis. High sensitivity and specificity are reported for F‐18 fluorodeoxyglucose (FDG) positron emission tomography (PET) staging in potentially resectable NSCLC. The authors investigated FDG‐PET staging in radical RT candidates with unresectable NSCLC.

[1]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[2]  J. Matthews,et al.  Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. , 2000, International journal of radiation oncology, biology, physics.

[3]  D. Mankoff,et al.  Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  G. V. von Schulthess,et al.  Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.

[5]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Ramsay,et al.  The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. , 1995, Chest.

[7]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose , 1994 .

[8]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[9]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[10]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[12]  A. Perruchoud,et al.  Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. , 1991, Thorax.

[13]  S Kramer,et al.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non‐oat‐cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group , 1980, Cancer.

[14]  R. Macklis,et al.  Intensity-modulated radiotherapy: rethinking basic treatment planning paradigms. , 2000, International journal of radiation oncology, biology, physics.

[15]  D. Joseph,et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  A. Hogg,et al.  High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[17]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[18]  D. Ettinger,et al.  Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. , 1997, International journal of radiation oncology, biology, physics.

[19]  L. Lamki.  Positron emission tomography, bronchogenic carcinoma, and the adrenals. , 1997, AJR. American journal of roentgenology.

[20]  M. Parmar,et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.

[21]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[22]  P. Marsden,et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer , 1994, The Lancet.

[23]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[24]  P. Rubin,et al.  Prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung , 1980 .

[25]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[26]  A. Fischman.  Positron emission tomography in the clinical evaluation of metastatic cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[28]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[29]  D. Ball,et al.  Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[30]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.